Solvias Unveils Innovations in CGT Quality Control Systems
At an upcoming conference, Solvias, a prominent provider in the field of chemistry, manufacturing, and controls (CMC), is set to highlight its groundbreaking NGS-based GMP quality control strategies for cell and gene therapy (CGT) manufacturing. This presentation underscores the importance of advanced analytical applications that enhance the quality control process in CGT production.
Conference Overview
William Mauck, the Team Lead Manager at Solvias's Molecular Biology Lab, will lead a session at the Cell & Gene Therapy International conference. This event, co-located with BioProcess International, brings together top experts who will share insights into the evolving landscape of next-generation therapies. The event aims to discuss innovative manufacturing, rigorous analytics, and strategies to ensure that treatments are both safe and effective for patients around the globe.
Key Presentation Themes
The session, titled "Multilayered QC in CGT: From Vector Fidelity to Epigenetic Regulation", will address significant challenges in CGT manufacturing. Mauck's presentation will delve into sophisticated analytical techniques that improve the accuracy of large molecule characterization, vector insertion mapping, and adventitious virus detection through next-generation sequencing (NGS). There will also be discussions regarding the future potential of epigenetic testing in ensuring the quality of CGT products.
Importance of Multilayered QC
Mauck emphasizes the value of multilayered quality control in CGT production. He states, "These methodologies integrate powerful tools like real-time genomic monitoring, precise vector validation, and early contaminant detection. Such capabilities are vital for ensuring that therapies are consistent, safe, and effective during their development phases."
Advancements in Cell and Gene Therapy
Solvias's approach aims to assist CGT developers in enhancing product reliability and responding effectively to increasing regulatory expectations. By employing next-generation techniques, the company seeks to facilitate the responsible and reliable scaling of CGT, ensuring that patients receive the highest quality treatments.
Session Details at CGTI 2025
The upcoming session at the Cell & Gene Therapy International 2025 will cover various aspects of manufacturing and analytics. It will focus on strategies for scaling autologous, allogeneic, and gene-edited therapies, maintaining a strong emphasis on quality and financial returns.
Event Schedule
The details for Mauck's talk at the conference are as follows:
- Track: Manufacturing & Analytics
- Title: Multilayered QC in CGT: From Vector Fidelity to Epigenetic Regulation
- Date/Time: Wednesday, September 17, 2025, from 3:15 to 3:45 PM ET
About Solvias
For over 25 years, Solvias has established itself as a leader in CMC analytics for the global life sciences sector. With a team comprising experts in the field, the company offers a full spectrum of services, from testing raw materials to drug product release and active pharmaceutical ingredient (API) development for small molecules. Located near Basel, Switzerland, Solvias adheres to stringent ISO, cGMP, GLP, and FDA standards across its six globally positioned Centers of Excellence.
Frequently Asked Questions
What is the focus of Solvias's presentation at the CGTI conference?
Solvias will focus on multilayered quality control in cell and gene therapy manufacturing, particularly emphasizing NGS-based GMP strategies.
Who will be presenting for Solvias at the conference?
William Mauck, the Team Lead Manager of the Molecular Biology Lab at Solvias, will be leading the presentation.
What are some analytical strategies highlighted by Solvias?
Innovative strategies include large molecule characterization, vector insertion mapping, and virus detection using next-generation sequencing.
Why is multilayered QC important in CGT?
It ensures consistent, safe, and effective manufacturing of therapies, addressing critical challenges in quality control.
What is the duration of Mauck's presentation?
The presentation is scheduled for 30 minutes, from 3:15 to 3:45 PM ET.
